Virtual reality for COPD exacerbation: A randomized controlled trial

MakaleYalnız künyeScopus SJRQ1
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Background: Pulmonary rehabilitation (PR) is an effective treatment method for chronic obstructive pulmonary disease (COPD). However, individuals with chronic diseases that require lifelong treatment and experience exacerbations need motivational methods. Objectives: The aim of this study was to examine the effects of virtual reality on symptoms, daily living activity, functional capacity, anxiety and depression levels in COPD exacerbation. Methods: Fifty patients hospitalized for COPD exacerbation were included in the study. They were randomly assigned to two groups. Twenty-five patients participated in a traditional PR (once-daily until discharge), including pedaling exercises. The second/25 patients followed the same protocol but experienced cycling simulation in the forest via virtual reality (VR + PR). All patients were evaluated using 1-minute/Sit-to-Stand test (STST), modified-Medical Research Council (mMRC) scale, COPD Assessment test (CAT), Hospital Anxiety and Depression Scale (HADS), and London Chest Activities of Daily Living (LCADL) before and after the treatment. Results: The STST showed an increase in both groups post-treatment, notably higher in the VR + PR (p = 0.037). Dyspnea levels and CAT scores decreased in all patients, but the decrease was greater in the PR + VR group for both parameters (p = 0.062, p = 0.003; respectively). Both groups experienced a reduction in the HADS scores compared to the pre-treatment, with a more significant decrease in depression and the total score in the VR + PR (p < 0.05). LCADL's sub-parameters and total score, excluding household, decreased in both groups after treatment (p < 0.05). The improvement was more substantial in the VR + PR. Conclusions: Virtual reality provides benefits in the management of COPD exacerbations and can be used safely. Clinical trial registiration: Registered at clinicaltrials.gov, registration ID: NCT05687396, URL: www.clinicaltrials.gov.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/munzur/2032Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.rmed.2024.107696Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
11
WoS
11
OpenAlex
15
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKizmaz, Erhan
dc.contributor.authorTelli Atalay, Orçin
dc.contributor.authorÇetin, Nazlı
dc.contributor.authorUğurlu, Erhan
dc.date.accessioned2026-10-28T14:54:51.419588521Z
dc.date.available2026-10-28T14:54:51.419588521Z
dc.date.issued2024
dc.description.abstractBackground: Pulmonary rehabilitation (PR) is an effective treatment method for chronic obstructive pulmonary disease (COPD). However, individuals with chronic diseases that require lifelong treatment and experience exacerbations need motivational methods. Objectives: The aim of this study was to examine the effects of virtual reality on symptoms, daily living activity, functional capacity, anxiety and depression levels in COPD exacerbation. Methods: Fifty patients hospitalized for COPD exacerbation were included in the study. They were randomly assigned to two groups. Twenty-five patients participated in a traditional PR (once-daily until discharge), including pedaling exercises. The second/25 patients followed the same protocol but experienced cycling simulation in the forest via virtual reality (VR + PR). All patients were evaluated using 1-minute/Sit-to-Stand test (STST), modified-Medical Research Council (mMRC) scale, COPD Assessment test (CAT), Hospital Anxiety and Depression Scale (HADS), and London Chest Activities of Daily Living (LCADL) before and after the treatment. Results: The STST showed an increase in both groups post-treatment, notably higher in the VR + PR (p = 0.037). Dyspnea levels and CAT scores decreased in all patients, but the decrease was greater in the PR + VR group for both parameters (p = 0.062, p = 0.003; respectively). Both groups experienced a reduction in the HADS scores compared to the pre-treatment, with a more significant decrease in depression and the total score in the VR + PR (p < 0.05). LCADL's sub-parameters and total score, excluding household, decreased in both groups after treatment (p < 0.05). The improvement was more substantial in the VR + PR. Conclusions: Virtual reality provides benefits in the management of COPD exacerbations and can be used safely. Clinical trial registiration: Registered at clinicaltrials.gov, registration ID: NCT05687396, URL: www.clinicaltrials.gov.
dc.description.sponsorshipPamukkale University Scientific Research Projects Coordination Unit, (2022SABE006)
dc.identifier.articlenumber107696
dc.identifier.doi10.1016/j.rmed.2024.107696
dc.identifier.eissn1532-3064
dc.identifier.issn0954-6111
dc.identifier.pmid38857811
dc.identifier.scopus2-s2.0-85195458063
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/munzur/2032
dc.identifier.volume230
dc.identifier.wosWOS:001256434700001
dc.language.isoen
dc.publisherW.B. Saunders Ltd
dc.relation.ispartofRespiratory Medicine
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCOPD
dc.subjectExacerbation
dc.subjectPulmonary rehabilitation
dc.subjectVirtual reality
dc.subject.classificationCardiac & Cardiovascular Systems
dc.subject.classificationRespiratory System
dc.subject.classificationCardiovascular System & Cardiology
dc.subject.otherActivities of Daily Living
dc.subject.otherAged
dc.subject.otherAnxiety
dc.subject.otherDepression
dc.subject.otherDisease Progression
dc.subject.otherDyspnea
dc.subject.otherExercise Therapy
dc.subject.otherFemale
dc.subject.otherHumans
dc.subject.otherMale
dc.subject.otherMiddle Aged
dc.subject.otherPulmonary Disease, Chronic Obstructive
dc.subject.otherTreatment Outcome
dc.subject.otherVirtual Reality
dc.subject.otherC reactive protein
dc.subject.otheradult
dc.subject.otheranxiety disorder
dc.subject.otherArticle
dc.subject.otherchronic obstructive lung disease
dc.subject.othercontrolled study
dc.subject.otherCOPD assessment test
dc.subject.othercycling
dc.subject.otherdaily life activity
dc.subject.otherdisease exacerbation
dc.subject.otherexercise
dc.subject.otherforced expiratory volume
dc.subject.otherforced vital capacity
dc.subject.otherfunctional status
dc.subject.otherHospital Anxiety and Depression Scale
dc.subject.otherhospitalization
dc.subject.otherhuman
dc.subject.otherleisure
dc.subject.othermajor clinical study
dc.subject.otherneurorehabilitation
dc.subject.otherprotein blood level
dc.subject.otherpulmonary rehabilitation
dc.subject.otherrandomized controlled trial
dc.subject.otherself care
dc.subject.othersingle blind procedure
dc.subject.othersit-to-stand test
dc.subject.otheretiology
dc.subject.otherkinesiotherapy
dc.subject.otherpathophysiology
dc.subject.otherprocedures
dc.subject.otherpsychology
dc.subject.otherrehabilitation
dc.subject.othertherapy
dc.titleVirtual reality for COPD exacerbation: A randomized controlled trial
dc.typeArticle
rdl.citation.openalex15
rdl.citation.scopus11
rdl.citation.wos11
rdl.departmentMunzur University, Health Science Faculty, Tunceli, Turkiye
rdl.departmentPamukkale University, Physiotherapy and Rehabilitation Faculty, Denizli, Turkiye
rdl.departmentPamukkale University, Pulmonology Department, Denizli, Turkiye
rdl.oa.statusclosed
rdl.scopus.quartileQ1
rdl.sdgSDG03
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)